Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon

Annals of the New York Academy of Sciences

Volumn 1053, Issue , 2005, Pages 289-300

  Abraini, Jacques H ^a,b   David, Hélène N ^b   Lemaire, Marc ^c  

^a GIP CYCERON   (France)

^b NNOXe Pharmaceuticals Inc   (Canada)

^c AIR LIQUIDE   (France)

Author keywords

Amphetamine sensitization; Anesthetic gases; Drug addiction; Ischemia induced brain damage; Neuroprotection; Neurotoxicity; Nitrous oxide; NMDA receptor antagonists; Xenon

Indexed keywords

AMPHETAMINE; CALCIUM ION; HALOTHANE; INHALATION ANESTHETIC AGENT; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NITROUS OXIDE; OXYGEN; XENON;

ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN BLOOD FLOW; BRAIN INFARCTION; BRAIN INFARCTION SIZE; CALCIUM TRANSPORT; CARDIOPULMONARY BYPASS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG METABOLISM; MIDDLE CEREBRAL ARTERY OCCLUSION; MINIMUM LUNG ALVEOLUS CONCENTRATION; MOUSE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; RAT; STROKE;

ANIMALIA; RODENTIA;

EID: 29744441529     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1344.025     Document Type: Conference Paper

References (52)

1. PARSONS, G.G., W. DANYSZ & G. QUACK. 1998. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11: 523-569.
2. OLNEY, J.W., J. LABRUYERE & M.T. PRICE. 1989. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244: 1360-1362.
3. OLNEY, J.W., J. LABRUYERE, G. WANG et al. 1991. NMDA antagonist neurotoxicity mechanism and prevention. Science 254: 1515-1518.
4. FIX, A.S., J.W. HORN, K.A. WIGHTMAN et al. 1993. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp. Neurol. 123: 204-215.
5. PULVIRENTI, L. & G.F. KOOB. 2002. Being partial to psychostimulant addiction therapy. Trends Pharmacol. Sci. 23: 151-153.
6. PALMER, G.C. & D. WIDZOWSKI. 2000. Low affinity use-dependent NMDA receptor antagonists show promise for clinical development. Amino Acids 19: 151-155.
7. KRASOWSKI, M.D. & N.L. HARRISON. 1999. General anaesthetic actions on ligand-gated ion channels. Cell. Mol. Life Sci. 55: 1278-1303.
8. JEVTOVIC-TODOROVIC, V., S.M. TODOROVIC, S. MENNERICK et al. 1998. Nitrous oxide (laughing gas) is an NMDA antagonist, neuroprotectant, and neurotoxin. Nat. Med. 4: 460-463.
9. FRANKS, N.P., R. DICKINSON, S.L.M. DE SOUSA et al. 1998. How does xenon produce anesthesia? Nature 396: 324.
10. YAMAKURA, T. & R.A. HARRIS. 2000. Effects of gaseous anesthetics nitrous oxide and xenon on ligand-gated ion channels: comparison with isoflurane and ethanol. Anesthesiology 93: 1095-1101.
11. WILHELM, S., D. MA, M. MAZE & N.P. FRANKS. 2002. Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology 96: 1485-1491.
12. PETZELT, C., P. BLOM, W. SCHMEHL et al. 2003. Prevention of neurotoxicity in hypoxic cortical neurons by the noble gas xenon. Life Sci. 72: 1909-1918.
13. ALTSCHULER, E.L. 2001. Xenon as neuroprotectant in acute stroke? Med. Hypotheses 56: 227-228.
14. DAVID, H.N., F. LÉVEILLÉ, L. CHAZALVIEL et al. 2003. Reduction of ischemic brain damage by nitrous oxide and xenon. J. Cereb. Blood Flow Metab. 23: 1168-1173.
15. HOMI, H.M., N. YOKOO, D. MA et al. 2003. The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology 99: 876-881.
16. ABRAINI, J.H., H.N. DAVID, O. NICOLE et al. 2004. Neuroprotection by nitrous oxide and xenon and its relation to minimum alveolar concentration. Anesthesiology 101: 260-261.
17. WONG, E.H., J.A. KEMP, T. PRIESTLEY et al. 1986. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. USA 83: 7104-7108.
18. OLNEY, J.W., M.T. PRICE, K. SALLES et al. 1987. MK-801 powerfully protects against N-methyl-D-aspartate neurotoxicity. Eur. J. Pharmacol. 141: 357-361.
19. NAGATA, A., S. NAKAO, N. NISHIZAWA et al. 2001. Xenon inhibits but N(2)O enhances ketamine-induced c-fos expression in the rat posterior cingulate and retrosplenial cortices. Anesth. Analg. 92: 362-368.
20. MA, D., S. WILHELM, M. MAZE & N.P. FRANKS. 2002. Neuroprotective and neurotoxic properties of the "inert" gas, xenon. Br. J. Anaesth. 89: 739-746.
21. MA, D., M. HOSSAIN, N. RAJAKUMARASWAMY et al. 2003. Combination of xenon and isoflurane produces a synergistic protective effect against oxygen-glucose deprivation injury in a neuronal-glial co-culture model. Anesthesiology 99: 748-751
22. PETZELT, C., P. BLOM, W. SCHMEHL et al. 2005. Xenon prevents cellular damage in differentiated PC-12 cells exposed to hypoxia. BMC Neurosci. 5: 55.
23. JEVTOVIC-TODOROVIC, V., N. BENSHOFF & J.W. OLNEY. 2000. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br. J. Pharmacol. 130: 1692-1698.
24. WILLIAMSON, P.B., D. MA, M. HOSSAIN et al. 2004. Xenon does not cause apoptotic neurodegeneration in the neonatal rat and protects against isoflurane-induced apoptosis. Anesthesiology 101: A864.
25. GOLDBERG, M.P. & D.W. CHOI. 1993. Combined oxygen and glucose deprivation in cortical cell culture: calcium-dependent and calcium-independent mechanisms of neuronal injury. J. Neurosci. 13: 3510-3524.
26. MA, D., H. YANG, J. LYNCH et al. 2003. Xenon attenuates cardiopulmonary bypass-induced neurologic and neurocognitive dysfunction in the rat. Anesthesiology 98: 690-698.
27. YOKOO, N., H. SHENG, J. MIXCO et al. 2004. Intraischemic nitrous oxide alters neither neurologic nor histologic outcome: a comparison with dizocilpine. Anesth. Analg. 99: 896-903.
28. ABRAINI, J.H., H.N. DAVID, E.T. MACKENZIE et al. 2004. Post-ischemic nitrous oxide alone vs. intra-ischemic nitrous oxide in the presence of isoflurane: what may it change for neuroprotection against cerebral stroke in the rat? Anesth. Analg. In press.
29. GOTO, T., K. SUWA, S. UEZONO et al. 1998. The blood-gas partition coefficient of xenon may be lower than generally accepted. Br. J. Anaesth. 80: 255-256.
30. FIELD, L.M., D.E. DORRANCE, E.K. KRZEMINSKA & L.Z. BARSOUM. 1993. Effect of nitrous oxide on cerebral blood flow in normal humans. Br. J. Anaesth. 70: 154-159.
31. REINSTRUP, P., E. RYDING, L. ALGOTSSON et al. 1994. Effects of nitrous oxide in human regional blood flow and isolated pial arteries. Anesthesiology 81: 396-402.
32. YAO, L.P., J. BANDRES, E.M. NEMOTO et al. 1992. Effect of 33% xenon inhalation on whole-brain blood flow and metabolism in awake and fentanyl-anesthetized monkeys. Stroke 23: 69-74.
33. WHITEHURST, S.L., E.M. NEMOTO, L. YAO & H. YONAS. 1994. MAC of xenon and halothane in rhesus monkeys. J. Neurosurg. Anesthesiol. 6: 275-279.
34. FRIETSCH, T., R. BOGDANSKI, R. BLOBNER et al. 2001. Effects of xenon on cerebral blood flow and cerebral glucose utilization in rats. Anesthesiology 94: 290-297.
35. SCHMIDT, M., T. MARX, C. PAPP-JAMBOR et al. 2002. Effect of xenon on cerebral autoregulation in pigs. Anesthesia 57: 960-966.
36. EGER, E.I., II, L.J. SAIDMAN & B. BRANDSTATER. 1965. Minimum alveolar anesthetic concentration: a standard of anesthetic potency. Anesthesiology 26: 756-763.
37. SCHMIDT, M., T. MARX, J. KOTZERKE et al. 2001. Cerebral and regional organ perfusion in pigs during xenon anesthesia. Anesthesia 56: 1154-1159.
38. DAYNES, G. 1989. The initial management of alcoholism using oxygen and nitrous oxide: a transcultural study. Int. J. Neurosci. 49: 83-86.
39. DAYNES, G. & M.A. GILLMAN. 1994. Psychotropic analgesic nitrous oxide prevents craving after withdrawal for alcohol, cannabis, and tobacco. Int. J. Neurosci. 76: 13-16.
40. GILLMAN, M.A. & F.J. LICHTIGFELD. 1991. Placebo and analgesic nitrous oxide for treatment of the alcohol withdrawal state. Br. J. Psychiatry 159: 672-675.
41. GILLMAN, M.A. & F.J. LICHTIGFELD. 2004. Correct use of analgesic nitrous oxide for the alcohol withdrawal state is essential. J. Clin. Psychopharmacol. 124: 238-239.
42. LICHTIGFELD, F.J. & M.A. GILLMAN. 1994. Psychotropic analgesic nitrous oxide and neurotransmitter mechanisms involved in the alcohol withdrawal state. Int. J. Neurosci. 76: 17-33.
43. OJUTKANGAS, R. & M.A. GILLMAN. 1994. Psychotropic analgesic nitrous oxide for treating alcohol withdrawal in an outpatient setting. Int. J. Neurosci. 76: 35-39.
44. ALHO, H., T. METHUEN, M. PALOHEIMO et al. 2002. Long-term effects of and physiological responses to nitrous oxide gas treatment during alcohol withdrawal: a double-blind, placebo-controlled trial. Alcohol Clin. Exp. Res. 26: 1816-1822.
45. ALHO, H., T. METHUEN, M. PALOHEIMO et al. 2003. Nitrous oxide has no effect in the treatment of alcohol withdrawal syndrome: a double-blind placebo-controlled randomized trial. J. Clin. Psychopharmacol. 23: 211-214.
46. WOLF, M.E. 1998. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. 54: 679-720.
47. HORNBEIN, T.F., E.I. EGER II, P.M. WINTER et al. 1982. The minimum alveolar concentration of nitrous oxide in man. Anesth. Analg. 61: 553-556.
48. CULLEN, S.C., E.I. EGER II, B.F. CULLEN & P. GREGORY. 1969. Observations of the anesthetic effect of the combination of xenon and halothane. Anesthesiology 31: 305-309.
49. LUTTROPP, H.H., R. THOMASSON, S. DAHM et al. 1994. Clinical experience with minimal flow xenon anesthesia. Acta Anesthesiol. Scand. 38: 121-125.
50. LYNCH, C., III, J. BAUM & R. TENBRICK. 2000. Xenon anesthesia. Anesthesiology 92: 865-868.
51. LOUIS-FERDINAND, R.T. 1994. Myelotoxic, neurotoxic, and reproductive adverse effects of nitrous oxide. Adverse Drug React. Toxicol. Rev. 13: 193-206.
52. WEIMANN, J. 2003. Toxicity of nitrous oxide. Best Pract. Res. Clin. Anaesthesiol. 17: 47-61.